MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.32
-0.56
-1.44%
Closed 16:00 07/10 EDT
OPEN
39.57
PREV CLOSE
38.88
HIGH
39.60
LOW
38.00
VOLUME
89.81K
TURNOVER
--
52 WEEK HIGH
43.24
52 WEEK LOW
35.00
MARKET CAP
4.96B
P/E (TTM)
-120.3518
1D
5D
1M
3M
1Y
5Y

LEGN News

More
J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels
TipRanks · 4d ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Jefferies Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $47
Jefferies initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and announces Price Target of $47.
Benzinga · 07/01 09:58
JP Morgan Initiates Coverage On Legend Biotech with Overweight Rating, Announces Price Target of $50
JP Morgan initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Target of $50.
Benzinga · 07/01 09:57
Morgan Stanley Initiates Coverage On Legend Biotech with Overweight Rating, Announces Price Target of $55
Morgan Stanley initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Target of $55.
Benzinga · 06/30 12:27
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
Legend Biotech Announces Three New Appointments to the Board of Directors
Business Wire · 06/09 21:35
Legend Biotech Corporation Announces Closing of Initial Public Offering
Business Wire · 06/09 21:30

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About LEGN

Legend Biotech Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). It is also developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL. The Company also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.
More

Webull offers kinds of Legend Biotech Corp stock information, including NASDAQ:LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.